Vitamin D3 for Life

Live Enlightened

Physiology

Vitamin D and Adult Functional Outcomes: Study Summary

Previous related pageVitamin D and Adult Functional Outcomes: Full Evidence ReviewNext related pageVitamin D and Adult Functional Outcomes: Full Evidence Review
Study at a glance

What question did the studies ask?

Does vitamin D change diabetes, infections, autoimmune disease or fractures in adults? Autoimmune disease means the immune system attacks the body’s own tissues. Trials mainly involved middle-aged or older people. Some had blood sugar above normal but below the diabetes threshold. Treatments included vitamin D3 and, in one trial, an active vitamin D-like drug.

What did they find?

A combined analysis found a modest reduction in progression to diabetes, although the main comparisons in the individual diabetes trials were uncertain. Other trials did not demonstrate fewer respiratory infections or fractures with vitamin D alone. Later confirmation of autoimmune cases weakened an earlier positive estimate.

What does this mean?

The answer depends on the outcome and who was studied. A higher vitamin D blood result does not prove better health in every system. An uncertain trial result also does not mean vitamin D has no normal role.

What are the limits?

Young adults and some severely deficient groups were less well represented. Trials differed in treatments and other supplements. Some reported harms. One report available only as an abstract described more deaths; its full paper could not be assessed. These findings do not establish a personal dose or blood target.

Read the full article below ↓

This review asks whether vitamin D changes meaningful adult outcomes, including diabetes, infections, autoimmune disease and fractures. Autoimmune diseases are conditions in which the immune system attacks the body’s own tissues. It compares clinical trials rather than assuming a higher vitamin D blood result means better health in every system. Read the detailed assessment, Vitamin D and Adult Functional Outcomes: Full Evidence Review.

What did the studies examine?

Participants were mainly middle-aged or older. Some had prediabetes, meaning blood sugar was above the normal range but below the diabetes threshold. Most large trials did not recruit only people with severe vitamin D deficiency.

Treatments differed. Vitamin D3 is a nutritional form. Eldecalcitol is an active vitamin D analogue, a drug with different handling in the body. One infection trial tested an offer of testing and supplementation rather than a comparison in which participants and researchers did not know which study pill was assigned.

What did they find?

The main planned comparisons in the individual D2d and DPVD diabetes trials did not show a clear benefit. A later analysis combining three trials found a modest reduction in progression to diabetes. That positive combined finding matters, but it does not establish a personal dose or blood target. For the metabolic background, see Vitamin D and Metabolism.

CORONAVIT did not demonstrate fewer respiratory infections. Many controls took vitamin D outside the trial, limiting the treatment comparison.

An early VITAL report suggested fewer autoimmune diseases. Later confirmation of cases weakened the estimate even for the original treatment period. The update cannot be explained only as benefit disappearing after treatment stopped. The detailed immune comparison is Vitamin D, Immune Tolerance Mechanisms and Autoimmune Outcomes: Full Evidence Review.

VITAL did not demonstrate fewer fractures with vitamin D alone. A smaller trial found a small improvement in calcium absorption in an analysis that accounted for starting differences without demonstrated improvements in the main bone, muscle or physical-function outcomes. Some trials combining calcium with vitamin D found fracture benefits, but those effects cannot be assigned to vitamin D alone.

A separate analysis used UK Biobank records to study infection patterns. It did not assign vitamin D treatment by chance. Its estimates depended on assumptions and could not prove that supplements prevented infections.

What does this mean?

Different outcomes give different answers. A change in a blood marker or laboratory test does not prove a clinical benefit. Equally, a trial without a clear benefit does not show that vitamin D has no normal role in the body. For the distinction between blood measurements and function, see Functional Vitamin D Status.

What are the limits?

Results depend on who was studied, the compound, other treatments and follow-up. Evidence in healthy young adults and some severely deficient groups is limited. Safety cannot be assumed: some studies reported adverse effects, and one trial report, available here only as an abstract, reported more deaths with vitamin D. The full report could not be assessed.

The review does not establish that everyone benefits, that nobody benefits, or that a research dose is suitable for an individual.

Sources

Related reading

Original sources

Source

Vitamin D and Risk for Type 2 Diabetes in People With Prediabetes : A Systematic Review and Meta-analysis of Individual Participant Data From 3 Randomized Clinical Trials

Published in Pittas AG et al (2023).

Publication details

Vitamin D and Risk for Type 2 Diabetes in People With Prediabetes : A Systematic Review and Meta-analysis of Individual Participant Data From 3 Randomized Clinical Trials. Pittas AG et al. 2023. Annals of internal medicine. Volume 176(3); pages/article 355-363. DOI: 10.7326/m22-3018.

Read more →
Source

Vitamin D and Marine n-3 Fatty Acids for Autoimmune Disease Prevention: Outcomes Two Years After Completion of a Double-Blind, Placebo-Controlled Trial

Published in Costenbader KH et al (2024).

Publication details

Vitamin D and Marine n-3 Fatty Acids for Autoimmune Disease Prevention: Outcomes Two Years After Completion of a Double-Blind, Placebo-Controlled Trial. Costenbader KH et al. 2024. Arthritis & rheumatology (Hoboken, N.J.). Volume 76(6); pages/article 973-983. DOI: 10.1002/art.42811.

Read more →
Source

Effect of a test-and-treat approach to vitamin D supplementation on risk of all cause acute respiratory tract infection and covid-19: phase 3 randomised controlled trial (CORONAVIT)

Published in Jolliffe DA et al (2022).

Publication details

Effect of a test-and-treat approach to vitamin D supplementation on risk of all cause acute respiratory tract infection and covid-19: phase 3 randomised controlled trial (CORONAVIT). Jolliffe DA et al. 2022. BMJ (Clinical research ed.). Volume 378; pages/article e071230. DOI: 10.1136/bmj-2022-071230.

Read more →
Source

Vitamin D supplementation and adverse skeletal and non-skeletal outcomes in individuals at increased cardiovascular risk: Results from the International Polycap Study (TIPS)-3 randomized controlled trial

Published in Joseph P et al (2023).

Publication details

Vitamin D supplementation and adverse skeletal and non-skeletal outcomes in individuals at increased cardiovascular risk: Results from the International Polycap Study (TIPS)-3 randomized controlled trial. Joseph P et al. 2023. Nutrition, metabolism, and cardiovascular diseases : NMCD. Volume 33(2); pages/article 434-440. DOI: 10.1016/j.numecd.2022.11.001. Abstract-level background only; the complete principal paper was unavailable for appraisal.

Read more →